Photo of Jane Hobson

Jane E. Hobson

Partner
Baker & McKenzie LLP

Biography

Jane is a partner in the London M&A Group and is a member of the global M&A practice group. Jane is also a member of the Global Healthcare and Life Sciences Industry group steering committee, where she leads the Firm’s transactional strategy for clients in that sector and is a client service director for five of our large multinational healthcare clients. Jane focuses on cross-border mergers and acquisitions, licensing transactions and joint ventures.

Representative Legal Matters

  • Astellas: Advised on various matters including (i) the acquisition of Quethera, a clinical stage gene-therapy company; and (ii) the acquisition of Nanna Therapeutics, a clinical stage UK biotech.
  • Sandoz: Advised in relation to the sale of their Chinese business to Aspen in return for European rights to certain products as well as various other disposals/licensing transactions.
  • Servier: Advised on the acquisition of a potential treatment for Fragile X syndrome (FXS) from the biotechnology company Kaerus Bioscience.
  • CSL: Advised on its strategic collaboration and option agreement with privately held Dutch biotech company VarmX BV to develop novel treatments for blood disorders.
  • GSK: Advised on the separation of GSK’s global consumer healthcare business to form independently listed Haleon plc.
  • Galapagos NV: Advised on the sale of its Jyseleca business to Alfasigma S.p.A.
  • Lonza: Advised on its divestment of its manufacturing sites at Ploermel, France and Edinburgh, UK.
  • Platinum Equity: Advised on its USD 2.1 billion acquisition of J&J’s LifeScan business in over 70 countries.
  • ICU Medical: Advised on its USD 2.7 billion acquisition of Smiths Group plc’s Medical Division.
  • GSK: Advised on the divestment of its global Cephalosporin antibiotics business to Sandoz.
  • GSK: Advised on its joint venture with Pfizer's Consumer Healthcare business to create the World's largest over the counter healthcare business.
  • GSK: Advised on the divestment of a vaccine manufacturing business based in China as part of a competitive auction.
  • GSK: Advised on the divestment of its manufacturing site in Cork, Ireland to Thermo Fisher and in Canada to Bora Pharmaceuticals.

Admissions

  • England & Wales~United Kingdom (1993)

Education

  • College of Law at Lancaster Gate (S.F.E.) (1990)
  • Queen Mary College (LL.B.) (1989)

Languages

  • English
  • French
  • Spanish

Previous Offices

  • Palo Alto